Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAPTYSBIO, INCANAB · Entity 4640 | Director · President, CEO | February 10, 2022 | February 14, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAPTYSBIO, INC
Report date February 10, 2022 · Filed February 14, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.44 · Expires 2032-02-09 | Direct | 200,000 |
Reported balance
After 2022-02-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-02-10 · Grant · Acquired 200,000 · Balance 200,000 F1: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on February 10, 2023, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. F2: In addition to the remaining options to purchase 200,000 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 1,118,893 shares of common stock, which options vest according to their terms, and (ii) 68,600 shares of common stock held directly. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on February 10, 2023, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
F2: In addition to the remaining options to purchase 200,000 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 1,118,893 shares of common stock, which options vest according to their terms, and (ii) 68,600 shares of common stock held directly.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 10, 2022 Filed Feb 14, 2022 21:49 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $30.44 | $0.00 |
DisclosureSEC source: 0001209191-22-009341 · doc4.xml · derivative · entry 1 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-02-09 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on February 10, 2023, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. F2 · balance_after: In addition to the remaining options to purchase 200,000 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 1,118,893 shares of common stock, which options vest according to their terms, and (ii) 68,600 shares of common stock held directly. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 23:42 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 36,645 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001209191-21-070986 · doc4.xml · derivative · entry 5 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,645 shares Expires 2022-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option grant was issued on February 1, 2012, is fully vested and exercisable until its expiration date of January 31, 2022. F6 · balance_after: In addition to the remaining options to purchase 0 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 1,118,893 shares of common stock, which options vest according to their terms, and (ii) 68,600 shares of common stock held directly. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 23:42 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 5,522 | $36.40 | $201,026.20 |
DisclosureSEC source: 0001209191-21-070986 · doc4.xml · nonDerivative · entry 4 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,600 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.26 to $36.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 23:42 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 19,208 | $35.75 | $686,776.28 |
DisclosureSEC source: 0001209191-21-070986 · doc4.xml · nonDerivative · entry 3 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,122 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.26 to $36.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 23:42 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 11,915 | $34.89 | $415,756.05 |
DisclosureSEC source: 0001209191-21-070986 · doc4.xml · nonDerivative · entry 2 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,330 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.25 to $35.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 23:42 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 36,645 | $1.12 | $41,042.40 |
DisclosureSEC source: 0001209191-21-070986 · doc4.xml · nonDerivative · entry 1 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 22:20 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantCommon Stock | 964 | $22.03 | $21,236.92 |
DisclosureSEC source: 0001209191-21-065173 · doc4.xml · nonDerivative · entry 1 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,600 F1 · shares: Represents shares of Common Stock acquired pursuant to the Issuer's Employee Stock Purchase Plan ("ESPP"), for the purchase period through November 15, 2021. In accordance with the ESPP, these shares were purchased at 85% of the lesser of the closing price of the Issuer's Common Stock on May 17, 2021 and November 15, 2021. F2 · balance_after: In addition to the reporting person's common stock directly held as set forth in Table I above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 1,155,538 shares of common stock, which options vest according to their terms. Read SEC document |
| November 05, 2021 Filed Nov 5, 2021 22:24 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 14,302 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001209191-21-063263 · doc4.xml · derivative · entry 6 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,302 shares Expires 2021-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option grant was issued on December 9, 2011, is fully vested and exercisable until its expiration date of December 8, 2021. F3 · balance_after: In addition to the remaining options to purchase 0 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 1,155,538 shares of common stock, which options vest according to their terms, and (ii) 67,636 shares of common stock held directly. Read SEC document |
| November 05, 2021 Filed Nov 5, 2021 22:24 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 14,302 | $35.00 | $500,570.00 |
DisclosureSEC source: 0001209191-21-063263 · doc4.xml · nonDerivative · entry 4 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,636 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 05, 2021 Filed Nov 5, 2021 22:24 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 14,302 | $1.12 | $16,018.24 |
DisclosureSEC source: 0001209191-21-063263 · doc4.xml · nonDerivative · entry 3 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 22:24 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 6,059 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001209191-21-063263 · doc4.xml · derivative · entry 5 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,302 Underlying: Common Stock · 6,059 shares Expires 2021-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option grant was issued on December 9, 2011, is fully vested and exercisable until its expiration date of December 8, 2021. F3 · balance_after: In addition to the remaining options to purchase 0 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 1,155,538 shares of common stock, which options vest according to their terms, and (ii) 67,636 shares of common stock held directly. Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 22:24 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 6,059 | $35.00 | $212,065.00 |
DisclosureSEC source: 0001209191-21-063263 · doc4.xml · nonDerivative · entry 2 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,636 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 22:24 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 6,059 | $1.12 | $6,786.08 |
DisclosureSEC source: 0001209191-21-063263 · doc4.xml · nonDerivative · entry 1 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,695 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 21:53 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 36,646 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001209191-21-062481 · doc4.xml · derivative · entry 4 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,645 Underlying: Common Stock · 36,646 shares Expires 2022-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option grant was issued on January 31, 2012 and became fully vested as of January 31, 2016, and is exercisable until its expiration date of January 31, 2022. F5 · balance_after: In addition to the remaining options to purchase 36,645 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 1,139,254 shares of common stock, which options vest according to their terms, and (ii) 67,636 shares of common stock held directly. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 21:53 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 2,559 | $32.88 | $84,139.41 |
DisclosureSEC source: 0001209191-21-062481 · doc4.xml · nonDerivative · entry 3 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,636 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.85 to $32.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 21:53 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 34,087 | $32.27 | $1,099,967.04 |
DisclosureSEC source: 0001209191-21-062481 · doc4.xml · nonDerivative · entry 2 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,195 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.84 to $32.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 21:53 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 36,646 | $1.12 | $41,043.52 |
DisclosureSEC source: 0001209191-21-062481 · doc4.xml · nonDerivative · entry 1 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 26, 2021 Filed Oct 28, 2021 23:54 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 15,993 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001209191-21-061975 · doc4.xml · derivative · entry 3 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,291 Underlying: Common Stock · 15,993 shares Expires 2022-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option grant was issued on January 31, 2012 and became fully vested as of January 31, 2016, and is exercisable until its expiration date of January 31, 2022. F3 · balance_after: In addition to the remaining options to purchase 73,291 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 1,139,254 shares of common stock, which options vest according to their terms, and (ii) 67,636 shares of common stock held directly. Read SEC document |
| October 26, 2021 Filed Oct 28, 2021 23:54 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 15,993 | $30.00 | $479,790.00 |
DisclosureSEC source: 0001209191-21-061975 · doc4.xml · nonDerivative · entry 2 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,636 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 26, 2021 Filed Oct 28, 2021 23:54 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 15,993 | $1.12 | $17,912.16 |
DisclosureSEC source: 0001209191-21-061975 · doc4.xml · nonDerivative · entry 1 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,629 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 21:38 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001209191-21-057077 · doc4.xml · derivative · entry 2 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,361 Underlying: Common Stock · 10,000 shares Expires 2021-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option is fully vested and immediately exercisable. F2 · balance_after: In addition to the remaining options to purchase 20,361 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 1,208,177 shares of common stock, which options vest according to their terms, and (ii) 67,636 shares of common stock held directly. Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 21:38 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 10,000 | $1.12 | $11,200.00 |
DisclosureSEC source: 0001209191-21-057077 · doc4.xml · nonDerivative · entry 1 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,636 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2021 Filed May 13, 2021 20:50 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001209191-21-032377 · doc4.xml · derivative · entry 2 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,361 Underlying: Common Stock · 10,000 shares Expires 2021-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option is fully vested and immediately exercisable. F2 · balance_after: In addition to the remaining options to purchase 30,361 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 1,208,177 shares of common stock, which options vest according to their terms, and (ii) 57,636 shares of common stock held directly. Read SEC document |
| May 12, 2021 Filed May 13, 2021 20:50 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 10,000 | $1.12 | $11,200.00 |
DisclosureSEC source: 0001209191-21-032377 · doc4.xml · nonDerivative · entry 1 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,636 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 02:29 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 119,700 | $0.00 Strike: $29.70 | $0.00 |
DisclosureSEC source: 0001209191-21-010518 · doc4.xml · derivative · entry 1 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,700 Underlying: Common Stock · 119,700 shares Expires 2031-02-09 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on February 10, 2022, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| March 10, 2020 Filed Mar 10, 2020 21:02 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001209191-20-017742 · doc4.xml · derivative · entry 2 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,361 Underlying: Common Stock · 10,000 shares Expires 2021-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option is fully vested and immediately exercisable. F2 · balance_after: In addition to the remaining options to purchase 40,361 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 1,088,477 shares of common stock, which options vest according to their terms, and (ii) 47,636 shares of common stock held directly. Read SEC document |
| March 10, 2020 Filed Mar 10, 2020 21:02 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 10,000 | $1.12 | $11,200.00 |
DisclosureSEC source: 0001209191-20-017742 · doc4.xml · nonDerivative · entry 1 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,636 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2020 Filed Feb 6, 2020 22:46 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001209191-20-007246 · doc4.xml · derivative · entry 2 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,361 Underlying: Common Stock · 10,000 shares Expires 2021-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option is fully vested and immediately exercisable. F2 · balance_after: In addition to the remaining options to purchase 50,361 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 1,088,477 shares of common stock, which options vest according to their terms, and (ii) 37,636 shares of common stock held directly. Read SEC document |
| February 05, 2020 Filed Feb 6, 2020 22:46 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 10,000 | $1.12 | $11,200.00 |
DisclosureSEC source: 0001209191-20-007246 · doc4.xml · nonDerivative · entry 1 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,636 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2019 Filed Dec 17, 2019 23:28 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantEmployee Stock Option (Right to Buy) · Derivative | 280,000 | $0.00 Strike: $15.73 | $0.00 |
DisclosureSEC source: 0001209191-19-060981 · doc4.xml · derivative · entry 1 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Stock · 280,000 shares Expires 2029-12-12 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on December 6, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| November 22, 2019 Filed Nov 25, 2019 21:49 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001209191-19-057952 · doc4.xml · derivative · entry 2 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,361 Underlying: Common Stock · 10,000 shares Expires 2021-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option is fully vested and immediately exercisable. F2 · balance_after: In addition to the remaining options to purchase 60,361 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 808,477 shares of common stock, which options vest according to their terms, and (ii) 27,636 shares of common stock held directly. Read SEC document |
| November 22, 2019 Filed Nov 25, 2019 21:49 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 10,000 | $1.12 | $11,200.00 |
DisclosureSEC source: 0001209191-19-057952 · doc4.xml · nonDerivative · entry 1 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,636 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 21:00 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 454 | $76.31 | $34,644.74 |
DisclosureSEC source: 0001209191-19-036426 · doc4.xml · nonDerivative · entry 5 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,636 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F6 · balance_after: The Reporting Person also holds options to purchase up to an aggregate of 878,838 shares of common stock, which options vest according to their terms, in addition to the 17,636 shares of common stock held directly as set forth in Table I above. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 21:00 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 1,994 | $75.86 | $151,270.82 |
DisclosureSEC source: 0001209191-19-036426 · doc4.xml · nonDerivative · entry 4 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,090 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.24 to $76.13 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 21:00 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 5,000 | $74.68 | $373,412.50 |
DisclosureSEC source: 0001209191-19-036426 · doc4.xml · nonDerivative · entry 3 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,084 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.20 to $75.12 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 21:00 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 6,440 | $73.70 | $474,637.02 |
DisclosureSEC source: 0001209191-19-036426 · doc4.xml · nonDerivative · entry 2 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,084 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.20 to $74.15 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 21:00 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 8,540 | $72.64 | $620,384.88 |
DisclosureSEC source: 0001209191-19-036426 · doc4.xml · nonDerivative · entry 1 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,524 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.16 to $73.15 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 17, 2019 Filed Apr 18, 2019 22:34 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001209191-19-025283 · doc4.xml · derivative · entry 2 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,361 Underlying: Common Stock · 10,000 shares Expires 2021-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option is fully vested and immediately exercisable. F2 · balance_after: In addition to the remaining option to purchase 70,361 shares of common stock as set forth in Table II, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 808,477 shares of common stock, which options vest according to their terms, and (ii) 40,064 shares of common stock held directly. Read SEC document |
| April 17, 2019 Filed Apr 18, 2019 22:34 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 10,000 | $1.12 | $11,200.00 |
DisclosureSEC source: 0001209191-19-025283 · doc4.xml · nonDerivative · entry 1 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,064 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2019 Filed Feb 11, 2019 22:38 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantEmployee Stock Option (Right to Buy) · Derivative | 94,000 | $0.00 Strike: $68.89 | $0.00 |
DisclosureSEC source: 0001209191-19-009043 · doc4.xml · derivative · entry 1 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,000 Underlying: Common Stock · 94,000 shares Expires 2029-02-07 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on February 8, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| January 14, 2019 Filed Jan 17, 2019 00:11 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001209191-19-003997 · doc4.xml · derivative · entry 4 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,284 Underlying: Common Stock · 40,000 shares Expires 2022-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F4 · derivative.exercise_date: The stock option is fully vested and immediately exercisable. F5 · balance_after: In addition to the remaining options to purchase 89,284 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 705,554 shares of common stock, which options vest according to their terms, and (ii) 30,064 shares of common stock held directly. Read SEC document |
| January 14, 2019 Filed Jan 17, 2019 00:11 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 12,240 | $71.10 | $870,304.39 |
DisclosureSEC source: 0001209191-19-003997 · doc4.xml · nonDerivative · entry 3 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,064 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.00 to $71.60 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 14, 2019 Filed Jan 17, 2019 00:11 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 27,760 | $70.65 | $1,961,227.34 |
DisclosureSEC source: 0001209191-19-003997 · doc4.xml · nonDerivative · entry 2 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,304 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.99 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 14, 2019 Filed Jan 17, 2019 00:11 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 40,000 | $1.12 | $44,800.00 |
DisclosureSEC source: 0001209191-19-003997 · doc4.xml · nonDerivative · entry 1 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,064 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 14, 2018 Filed Dec 19, 2018 02:46 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 41,728 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001209191-18-063382 · doc4.xml · derivative · entry 5 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,284 Underlying: Common Stock · 41,728 shares Expires 2022-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: The stock option is fully vested and immediately exercisable. F6 · balance_after: In addition to the remaining options to purchase 129,284 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 705,554 shares of common stock, which options vest according to their terms, and (ii) 30,064 shares of common stock held directly. Read SEC document |
| December 14, 2018 Filed Dec 19, 2018 02:46 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 7,800 | $70.51 | $549,978.78 |
DisclosureSEC source: 0001209191-18-063382 · doc4.xml · nonDerivative · entry 4 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,064 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.33 to $70.98 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 14, 2018 Filed Dec 19, 2018 02:46 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 9,084 | $69.68 | $632,967.67 |
DisclosureSEC source: 0001209191-18-063382 · doc4.xml · nonDerivative · entry 3 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,864 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.31 to $70.30 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 14, 2018 Filed Dec 19, 2018 02:46 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 24,844 | $68.89 | $1,711,428.63 |
DisclosureSEC source: 0001209191-18-063382 · doc4.xml · nonDerivative · entry 2 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,948 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.31 to $69.30 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 14, 2018 Filed Dec 19, 2018 02:46 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 41,728 | $1.12 | $46,735.36 |
DisclosureSEC source: 0001209191-18-063382 · doc4.xml · nonDerivative · entry 1 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 01:06 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option · Derivative | 30,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001209191-18-062336 · doc4.xml · derivative · entry 11 Suria Hamza · CIK 0001654495 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,361 Underlying: Common Stock · 30,000 shares Expires 2021-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F8 · derivative.exercise_date: The stock option is fully vested and immediately exercisable. F9 · balance_after: In addition to the remaining options to purchase 80,361 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 796,205 shares of common stock, which options vest according to their terms, and (ii) 30,064 shares of common stock held directly. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.